LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Millennium Management LLC

Millennium Management LLC lessened its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 30.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 76,205 shares of the medical instruments supplier’s stock after selling 33,718 shares during the quarter. Millennium Management LLC owned about 0.34% of LeMaitre Vascular worth $6,270,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LMAT. F M Investments LLC purchased a new stake in shares of LeMaitre Vascular during the 2nd quarter valued at approximately $7,443,000. Congress Asset Management Co. MA raised its position in LeMaitre Vascular by 17.0% in the fourth quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock valued at $33,754,000 after purchasing an additional 86,293 shares during the period. Nicholas Investment Partners LP acquired a new position in shares of LeMaitre Vascular in the second quarter worth $3,900,000. Janus Henderson Group PLC grew its stake in shares of LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after acquiring an additional 47,218 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after acquiring an additional 38,303 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 target price for the company. Barrington Research restated an “outperform” rating and issued a $92.00 price objective on shares of LeMaitre Vascular in a research note on Friday, September 20th. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Finally, JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus price target of $94.40.

Insider Activity

In other news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at $168,944,956.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,275 shares of company stock worth $2,598,150 over the last ninety days. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Stock Down 3.9 %

NASDAQ LMAT opened at $89.28 on Friday. The stock has a market capitalization of $2.00 billion, a P/E ratio of 59.13, a P/E/G ratio of 2.41 and a beta of 0.88. LeMaitre Vascular, Inc. has a 52-week low of $44.27 and a 52-week high of $93.32. The firm has a 50-day moving average price of $87.88 and a 200 day moving average price of $80.32.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. During the same period last year, the company posted $0.37 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were given a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.72%. LeMaitre Vascular’s dividend payout ratio is presently 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.